Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK ‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan
Cancer Science · 2025
DOI: 10.1111/cas.70308 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Science, 2025. Verfasst von Tetsuya Mori und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan. Hauptthemen laut MEDLINE: Crizotinib, Lymphoma, Large-Cell, Anaplastic, Neuroblastoma, Anaplastic Lymphoma Kinase. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Collaboration, Pfizer, Health Labour Sciences Research, Ministry of Health, Labour and Welfare.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Clinical development of crizotinib in children with ALK‐positive anaplastic large cell lymphoma (ALCL) was advanced in the US but not in Japan. The objectives of phase 1 part of a clinical study in Japan were to assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of crizotinib in children with relapsed/refractory (R/R) ALK‐positive ALCL or neuroblastoma (NB). Two dose levels (165 and 280 mg/m 2 twice daily (BID)) were planned to be evaluated. The aim of phase 2 part of the study was to assess the antitumor activity of crizotinib at the RP2D in children with R/R ALK‐positive ALCL. Seven patients were eligible for phase 1 part, 5 with ALCL and 2 with NB. All 7 patients received crizotinib at a starting dose of 165 mg/m 2 BID, with 1 dose‐limiting toxicity observed (grade 3 gamma‐glutamyltransferase increased). The most common grade 3 or 4 adverse event was neutropenia (71%). The steady‐state C max and AUC tau of crizotinib at 165 mg/m 2 BID were higher than expected. Considering the risk of a greater incidence of severe neutropenia, we decided that the 165 mg/m 2 BID be the RP2D without evaluation at 280 mg/m 2 BID. A total of 11 patients with ALK‐positive ALCL were enrolled in the phase 2 part. The objective response rate was 72.7% (90% CI, 43.6%–92.1%). One patient permanently discontinued crizotinib due to disease progression. Crizotinib at 165 mg/m 2 BID was well tolerated and showed favorable antitumor activity in children with R/R ALK‐positive ALCL. Trial Registration: UMIN‐CTR: UMIN000028075
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
- Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.
- Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
- Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
- Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Tetsuya Mori, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi
Förderung
- Clinical Research Collaboration, Pfizer
- Health Labour Sciences Research
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Mori, T., Kada, A., Osumi, T., Tomizawa, D., Koga, Y., Fukano, R., Takeuchi, K., Tateishi, U., Miyazaki, O., Asada, R., Saito, A. M., Fukuhara, K., & Sekimizu, M. (2025). Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK ‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan. Cancer Science. https://doi.org/10.1111/cas.70308
Vancouver
Mori T, Kada A, Osumi T, Tomizawa D, Koga Y, Fukano R, et al. Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK ‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan. Cancer Science. 2025. doi:10.1111/cas.70308
BibTeX
@article{Mori2025,
author = {Mori, Tetsuya and Kada, Akiko and Osumi, Tomoo and Tomizawa, Daisuke and Koga, Yuhki and Fukano, Reiji and Takeuchi, Kengo and Tateishi, Ukihide and Miyazaki, Osamu and Asada, Ryuta and Saito, Akiko M and Fukuhara, Kei and Sekimizu, Masahiro},
title = {Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK ‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70308}
}
EUVIMED